Description
This blend combines two research compounds from different classes in a single injectable vial: Retatrutide (LY3437943), a triple-incretin agonist that simultaneously activates GLP-1, GIP and glucagon receptors, and Tesamorelin, a synthetic analog of growth-hormone-releasing hormone (GHRH). Retatrutide addresses the incretin axis across three receptor systems at once, with the glucagon component associated in research with increased energy expenditure and greater lipid breakdown. Tesamorelin acts at an entirely different site: as a selective agonist at the GHRH receptor of the pituitary, stimulating the body’s own pulsatile growth hormone release rather than supplying GH directly.
Both active ingredients are injectable peptides in their clinically studied form, and that is exactly how this blend ships: as a freeze-dried powder (lyophilizate) that you reconstitute with bacteriostatic water and administer subcutaneously. This matches the route on which the published studies are based. What still needs framing honestly: there are no robust clinical data on precisely this Reta-plus-Tesamorelin combination in one vial. The evidence stems from the individual compounds, and the two have very different dosing magnitudes, which makes the fixed 1:1 mix experimental.
The core research findings stem from the injectable individual compounds. For Retatrutide, phase 2 data showed body weight reductions of up to 24.2 percent after 48 weeks in study models with subjects who had obesity, and reductions in liver fat content in MASLD research. For Tesamorelin, pooled phase 3 studies documented significant reductions in visceral adipose tissue while preserving subcutaneous fat, alongside an increase in IGF-1. These findings apply to the respective subcutaneous mono-application, not to the combination.
You receive this blend as a research compound in 10 vials of 20 mg per vial (10 mg Retatrutide plus 10 mg Tesamorelin), as a lyophilizate for reconstitution. The format is intended for experimental research approaches.
This information is for research and educational purposes only. Not medical advice.
Studies
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial - NEJM 2023: Phase 2 data on the Retatrutide component (triple agonist), including the documented body weight reductions (subcutaneous).
- Effects of tesamorelin (TH9507), a GHRH analog, in patients with excess abdominal fat - pooled phase 3 analysis - J Clin Endocrinol Metab 2010: Pooled phase 3 data on the Tesamorelin component, visceral fat reduction and IGF-1 increase (subcutaneous).
- Efficacy and safety of tesamorelin - randomized double-blind trial - AIDS 2024: Recent randomized study with MRI quantification of visceral and hepatic fat under subcutaneous tesamorelin.
Stack Notes
- Tesamorelin solo (injectable) as a clean reference point: anyone wanting to study the GHRH component in its study-validated subcutaneous form in isolation gets, with pure Tesamorelin, the kinetics on which the published phase 3 data are based.
- Retatrutide solo (injectable) for the pure incretin axis: pure Retatrutide as a subcutaneous peptide matches the protocol studied in the phase 2 trials and is suited to evaluating the metabolic part of the blend in isolation.
- Ipamorelin as a GHRH-complementary GH secretagogue: in research the GHRH axis is often combined with a ghrelin receptor agonist such as Ipamorelin, since both address different pathways of GH release - mechanistically complementary to the Tesamorelin component.
- CJC-1295 with DAC as a longer-acting GHRH analog: anyone wanting to study the GHRH side with different kinetics will find in CJC-1295 with DAC a GHRH analog with substantially extended residence time compared to short-lived Tesamorelin.
- BPC-157 as a companion compound in recovery protocols: in peptide research BPC-157 is frequently studied alongside metabolic and GH-axis substances, since it addresses an independent tissue pathway.
